Y-mAbs Therapeutics, Inc.

YMAB · NASDAQ
Analyze with AI
6/30/2025
3/31/2025
12/31/2024
9/30/2024
Operating Activities
Net Income-$3,240-$5,196-$6,790-$6,998
Dep. & Amort.$53$71$102$121
Deferred Tax$0$0$0$0
Stock-Based Comp.$2,902$3,341$3,079$4,195
Change in WC$3,876-$4,315-$1,224-$4,378
Other Non-Cash-$1,940-$812$2,963-$3,605
Operating Cash Flow$1,651-$6,911-$1,870-$10,665
Investing Activities
PP&E Inv.$0-$127$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow$0-$127$0$0
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$332$114$986$979
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$0
Financing Cash Flow$332$114$986$979
Forex Effect$0$0-$4$2
Net Chg. in Cash$1,983-$6,924-$888-$9,684
Supplemental Information
Beg. Cash$60,310$67,234$68,122$77,806
End Cash$62,293$60,310$67,234$68,122
Free Cash Flow$1,651-$7,038-$1,870-$10,665